Derma Sciences, Inc. , a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers.
http://www.news-medical.net/news/20130426/Derma-Sciences-initiates-patient-screening-in-DSC127-pivotal-program-for-treatment-of-diabetic-foot-ulcers.aspx
http://www.news-medical.net/news/20130426/Derma-Sciences-initiates-patient-screening-in-DSC127-pivotal-program-for-treatment-of-diabetic-foot-ulcers.aspx
No comments:
Post a Comment